Priv.-Doz. Dr. Razvan Galalae

Studium der Medizin an der Universität Hamburg mit Abschluss der Ärztlichen Prüfung (Nov. 1989)

MedAustron

Chefarzt der Klinik für Radioonkologie an den Evangelischen Kliniken Gelsenkirchen

Stellvertretender Direktor Klinik für Strahlentherapie der Klinik Strahlentherapie der Ruhr Universität Bochum

Erteilung Strahlenschutzfachkunde Partikeltherapie

Spezialisierung Proton Therapy Center RPTC Munich + Senior Scientist und Senior Consultant am Paul Scherrer Institute Proton Therapy Center in Villigen/Schweiz

Stellvertretender Direktor der Klinik für Strahlentherapie, Universitätsklinikum Kiel

Habilitation im Fach Strahlentherapie – Lehrbefähigung (Juli 2005) + Venia Legendi (Juli 2005), Christian-Albrechts-Universität zu Kiel

Facharzt für Strahlentherapie, Christian-Albrechts-Universität zu Kiel

Doktorprüfung (Magna cum laude), Christian-Albrechts-Universität zu Kiel

Approbation

Gründungsmitglied der DEGRO (Deutsche Gesellschaft für Radioonkologie)

ESTRO (European Society for Therapeutic Radiology and Oncology)

ASTRO (American Society for Therapeutic Radiology and Oncology)

PTCOG (Particle Therapy Co-Operative Group)

aktives Mitglied der Quality of Life Group der EORTC

aktives Mitglied der GEC-ESTRO (European Brachytherapy Society), Breast Cancer Working Group

Pelak MJ, Flechl B, Mumot M, Galalae R, Tubin S, Hug E, Lütgendorf-Caucig C (2021) The value of SSTR2 receptor-targeted PET/CT in proton irradiation of grade I meningioma. Cancers; Sept. 2021 in press (manuscript ID: cancers-1343510)

Greimel E, Nagele E, Lanceley A, et al. EORTC Quality of Life Group. (2021) Psychometric validation of the European Organization for Research and Treatment of Cancer – Quality of Life Questionnaire Sexual health (EORTC QLQ-SH22).
Eur J Cancer 2021; 154(2): 235-245.

Singer S, Hammerlid E, Tomaszewska IM, et al. EORTC Quality of Life Group and the EORTC Head and Neck Cancer Group. (2021) Methodological approach for determining the Minimal Important Difference Change scores for the Performance of the European Organisation for Research and Treatment of Cancer Head and Neck Module (EORTC QLQ-HN43) exemplified by the Swallowing scale.
Qual Life Res Epub 05 July 2021

Tharavichitkul E, Muangwong P, Chakrabandhu S, et al. (2021) Comparison of clinical outcomes achieved with image-guided adaptive brachytherapy for cervix cancer using CT or transabdominal ultrasound.
Brachytherapy, 20(3): 543-549.

Hannoun-Lévi JM, Gal J, Van Limbergen E, et al. (2021) Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score-Matched Cohort Analysis of the GEC-ESTRO Breast Cancer Working Group Database.
Int J Radiat Oncol Biol Phys, 110(2): 452-461.

Domankevich V, Efrati M, Schmidt M, et al. (2020) RIG-1-Like Receptor Activation Synergizes With Intratumoral Alpha Radiation to Induce Pancreatic Tumor Rejection, Triple-Negative Breast Metastases Clearance, and Antitumor Immune Memory in Mice.
Front Oncol. 2020 Jul 17; 10:990. doi: 10.3389/fonc.2020.00990. eCollection 2020.

Murakami N, Nakamura S, Kashihara T, Kato T, et al. (2020) Hyaluronic acid gel injection in rectovaginal septum reduced incidence of rectal bleeding in brachytherapy for gynecological malignancies.
Brachytherapy. 2020 Mar-Apr; 19(2):154-161.

Galalae R, Hannoun-Lévi JM. (2020) Accelerated partial breast irradiation by brachytherapy: present evidence and future developments. (On invitation of the Japanese Society of Oncology)
Jpn J Clin Oncol. 2020 Jul 9; 50(7):743-752.